FDA revokes emergency use authorization of hydroxychloroquine for COVID-19

The U.S. Food and Drug Administration on Monday revoked the emergency use authorization for malaria drug hydroxychloroquine as a treatment for COVID-19, the use of which has been championed by U.S. President Donald Trump.

Donald Trump championed malaria drug's use for COVID-19 patients, said he took it himself

This Monday, April 6, 2020 file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. U.S. President Donald Trump and others in recent months touted the drug as a possible treatment for COVID-19. (John Locher/The Associated Press)

The U.S. Food and Drug Administration on Monday revoked the emergency use authorization for malaria drugs as a treatment for COVID-19 amid growing evidence they don't work and could cause deadly side effects.

U.S. President Donald Trump had championed the use of the drugs for COVID-19 and even said he had taken them himself.

But the FDA said based on new evidence, it was no longer reasonable to believe that oral formulations of hydroxychloroquine and the related drug chloroquine may be effective in treating the respiratory illness caused by the novel coronavirus.

The move comes after several studies of hydroxychloroquine suggested it was not effective, including a widely anticipated trial earlier this month showed it failed to prevent infection in people who have been exposed to the virus.

The drug's anti-inflammatory and antiviral properties suggested it might help treat COVID-19, and the FDA authorized its emergency use in March at the height of a pandemic caused by a virus for which there were no approved treatments.

Trump pushed drug's use

Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took it preemptively against infection after two people who worked at the White House were diagnosed with COVID-19.

At the White House Monday, Trump said other countries had provided great reports on the effectiveness of hydroxychloroquine for treatment of the coronavirus, complaining that only U.S. agencies have failed to grasp its benefit.

The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.

But doctors in recent weeks had already pulled back on the use of hydroxychloroquine as a COVID-19 treatment after several studies suggested it is not effective and may pose heart risks for certain patients.

The drug hydroxychloroquine is displayed by a pharmacist at the Rock Canyon Pharmacy in Provo, Utah, on May 27. The U.S. Food and Drug Administration on Monday revoked the emergency use authorization for treatment of COVID-19. (George Frey/Reuters)

Current U.S. government treatment guidelines do not recommend use of the malaria drugs for COVID-19 patients outside of a clinical trial.

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure and muscle or nerve damage.

Some clinical trials still ongoing

France, Italy and Belgium late last month moved to halt the use of hydroxychloroquine to treat COVID-19 patients. But the United States last month supplied Brazil with two million doses for use against the coronavirus, as the South American country has emerged as the pandemic's latest epicentre.

Meanwhile, some 400 trials are listed as using hydroxychloroquine or chloroquine as interventions for COVID-19, more than half of them still ongoing, according to a recent analysis from research firm GlobalData.

In the United States, the National Institute of Allergy and Infectious Diseases last month launched a trial designed to show whether hydroxychloroquine in combination with azithromycin can prevent hospitalization and death from COVID-19.

With files from The Associated Press and CBC News

Add some “good” to your morning and evening.

A variety of newsletters you'll love, delivered straight to you.

Sign up now


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?